View Post

Eli Lilly’s Verzenio data shows decrease in breast cancer recurrence

In Clinical Studies News by Barbara Jacoby

By: Aakash Babu From: seekingalpha.com Eli Lilly and Co (NYSE:LLY) posts new data for the investigational use of Verzenio (abemaciclib) in high-risk early breast cancer. In an exploratory analysis of a pre-specified subgroup of patients who received neoadjuvant chemotherapy (n=2,056), the addition of Verzenio to endocrine therapy (ET) resulted in a numerically greater effect size when compared to the intent-to-treat (ITT) …

View Post

Lilly reports positive PRO from high-risk early breast cancer trial

In Clinical Studies News by Barbara Jacoby

From: clinicaltrialsarena.com Eli Lilly has reported positive patient-reported outcomes (PRO) from a late-stage trial testing the efficacy of Verzenio (abemaciclib) in treating high-risk early breast cancer (EBC).  Eli Lilly has reported positive patient-reported outcomes (PRO) from a late-stage trial testing the efficacy of Verzenio (abemaciclib) in treating high-risk early breast cancer (EBC). The move comes after a primary outcome analysis …